Ahmed Ahmed Allam, Heba A Ahmed, Mohammad Ahmad Hassan, Safaa A A Khaled, Azza Shibl, Amira Mahmoud Osman, Nada Mohamed Rafat Ali, Nesma Mokhtar Ahmed
{"title":"程序性细胞死亡-1和程序性细胞死亡配体-1在儿童急性b淋巴细胞白血病中的表达及其作为生物标志物的意义。","authors":"Ahmed Ahmed Allam, Heba A Ahmed, Mohammad Ahmad Hassan, Safaa A A Khaled, Azza Shibl, Amira Mahmoud Osman, Nada Mohamed Rafat Ali, Nesma Mokhtar Ahmed","doi":"10.1111/ijlh.14472","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess programmed death-1 (PD-1) and programmed death ligand-1 (PDL-1) expression in newly diagnosed pediatric cases of acute B-lymphoblastic leukemia (B-ALL) and at 6 months of treatment and to explore their value as biomarkers.</p><p><strong>Methods: </strong>Fifty newly diagnosed B-ALL patients and 30 controls were recruited. Bone marrow samples or peripheral blood were obtained from children at diagnosis and 6 months after cytotoxic therapy. Flow cytometric analysis of obtained samples was done and the PD-1, PDL-1, and CD3 (cluster of differentiation) expressions were recorded.</p><p><strong>Results: </strong>Percentages of PD-1, PDL-1, and CD3 in the control and B-ALL groups at initial presentation were 7.9% ± 2.8% vs. 16.45% ± 7.7% (p = 0.023), 8.6% ± 3.4% vs. 19.05% ± 13.7% (p < 0.001), and 30.8% ± 1.2% vs. 11.05% ± 7.3% (p < 0.001), respectively. CD3 expression increased significantly at 6 months; PD-1 and PDL-1 expression showed insignificant decrease from initial presentation. There was a negative correlation between PD-1 and HB level (p = 0.03) and a positive correlation between PD-1 and PDL-1 at 6 months of treatment (p = 0.002). Remission rates increased significantly with the decrease of PD-1and PDL-1.</p><p><strong>Conclusion: </strong>Initially, PD-1 and PDL-1 were higher in patients than in controls and decreased 6 months after treatment. PD-1 and PDL-1 expression was associated with increased remission rates, implicating that modulation of PD-1 and PDL-1 expression may be a therapeutic approach for B-ALL. Moreover, this study created a new method for the assessment of PD-1 and PDL-1 in B-ALL.</p><p><strong>Clinical trial: </strong>Trial Registration: NCT05428111.</p>","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Programmed Cell Death-1 and Programmed Cell Death Ligand-1 in Childhood Acute B-Lymphoblastic Leukemia: Expression and Significance as Biomarker.\",\"authors\":\"Ahmed Ahmed Allam, Heba A Ahmed, Mohammad Ahmad Hassan, Safaa A A Khaled, Azza Shibl, Amira Mahmoud Osman, Nada Mohamed Rafat Ali, Nesma Mokhtar Ahmed\",\"doi\":\"10.1111/ijlh.14472\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This study aimed to assess programmed death-1 (PD-1) and programmed death ligand-1 (PDL-1) expression in newly diagnosed pediatric cases of acute B-lymphoblastic leukemia (B-ALL) and at 6 months of treatment and to explore their value as biomarkers.</p><p><strong>Methods: </strong>Fifty newly diagnosed B-ALL patients and 30 controls were recruited. Bone marrow samples or peripheral blood were obtained from children at diagnosis and 6 months after cytotoxic therapy. Flow cytometric analysis of obtained samples was done and the PD-1, PDL-1, and CD3 (cluster of differentiation) expressions were recorded.</p><p><strong>Results: </strong>Percentages of PD-1, PDL-1, and CD3 in the control and B-ALL groups at initial presentation were 7.9% ± 2.8% vs. 16.45% ± 7.7% (p = 0.023), 8.6% ± 3.4% vs. 19.05% ± 13.7% (p < 0.001), and 30.8% ± 1.2% vs. 11.05% ± 7.3% (p < 0.001), respectively. CD3 expression increased significantly at 6 months; PD-1 and PDL-1 expression showed insignificant decrease from initial presentation. There was a negative correlation between PD-1 and HB level (p = 0.03) and a positive correlation between PD-1 and PDL-1 at 6 months of treatment (p = 0.002). Remission rates increased significantly with the decrease of PD-1and PDL-1.</p><p><strong>Conclusion: </strong>Initially, PD-1 and PDL-1 were higher in patients than in controls and decreased 6 months after treatment. PD-1 and PDL-1 expression was associated with increased remission rates, implicating that modulation of PD-1 and PDL-1 expression may be a therapeutic approach for B-ALL. Moreover, this study created a new method for the assessment of PD-1 and PDL-1 in B-ALL.</p><p><strong>Clinical trial: </strong>Trial Registration: NCT05428111.</p>\",\"PeriodicalId\":94050,\"journal\":{\"name\":\"International journal of laboratory hematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of laboratory hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/ijlh.14472\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of laboratory hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/ijlh.14472","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Programmed Cell Death-1 and Programmed Cell Death Ligand-1 in Childhood Acute B-Lymphoblastic Leukemia: Expression and Significance as Biomarker.
Introduction: This study aimed to assess programmed death-1 (PD-1) and programmed death ligand-1 (PDL-1) expression in newly diagnosed pediatric cases of acute B-lymphoblastic leukemia (B-ALL) and at 6 months of treatment and to explore their value as biomarkers.
Methods: Fifty newly diagnosed B-ALL patients and 30 controls were recruited. Bone marrow samples or peripheral blood were obtained from children at diagnosis and 6 months after cytotoxic therapy. Flow cytometric analysis of obtained samples was done and the PD-1, PDL-1, and CD3 (cluster of differentiation) expressions were recorded.
Results: Percentages of PD-1, PDL-1, and CD3 in the control and B-ALL groups at initial presentation were 7.9% ± 2.8% vs. 16.45% ± 7.7% (p = 0.023), 8.6% ± 3.4% vs. 19.05% ± 13.7% (p < 0.001), and 30.8% ± 1.2% vs. 11.05% ± 7.3% (p < 0.001), respectively. CD3 expression increased significantly at 6 months; PD-1 and PDL-1 expression showed insignificant decrease from initial presentation. There was a negative correlation between PD-1 and HB level (p = 0.03) and a positive correlation between PD-1 and PDL-1 at 6 months of treatment (p = 0.002). Remission rates increased significantly with the decrease of PD-1and PDL-1.
Conclusion: Initially, PD-1 and PDL-1 were higher in patients than in controls and decreased 6 months after treatment. PD-1 and PDL-1 expression was associated with increased remission rates, implicating that modulation of PD-1 and PDL-1 expression may be a therapeutic approach for B-ALL. Moreover, this study created a new method for the assessment of PD-1 and PDL-1 in B-ALL.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
